Paroxysmal Nocturnal Hemoglobinuria (PNH) originates from an acquired genetic defect in a multipotent hematopoietic stem cell that becomes stem-cell-like in its ability to survive, expand, and self-renew. PNH is a rare condition characterized by intravascular hemolysis. PNH can arise anew or in the setting of an underlying bone marrow disorder such as aplastic anemia (AA), myelodysplastic syndrome (MDS), or primary myelofibrosis (PMF). This case presentation documents the challenging diagnosis of PNH in the obstetric setting, in which other possible causes for a hemolytic anemia could be considered. We discuss the management of a pregnancy in the presence of PNH in a low-to-middle income setting.
Laboratory investigations corroborating the diagnosis of PNH includes the presence of hemoglobinuria, a peripheral blood smear demonstrating red blood cell fragments and an elevated lactate dehydrogenase assay [4] . Clinical diagnosis of PNH may be confirmed with peripheral blood flow cytometry demonstrating the absence or severe deficiency of GPI-anchored proteins on at
IntroduCtIon
Paroxysmal nocturnal hemoglobinuria is a rare disease and the estimated prevalence of this disorder is in the range of one to ten cases per million population with estimates in the pregnant population being limited to case report data [1] . The median age of onset of PNH is in the mid-thirties and can affect women of childbearing age and in some instances PNH may be diagnosed in pregnancy for the first time [1, 2] . There is no demonstrable ethnic or geographic distribution of the disease [1] .
PNH represents the clonal expansion of hematopoietic stem cells that have an acquired somatic mutation in the phosphatidylinositol glycan-complementation class A (PIG-A) gene with a consequent deficiency of glycosyl phosphatidylinositol-anchored proteins including the complement-regulatory proteins CD55 and CD59. The clinical sequelae of the deficiency of these complement-regulatory proteins renders affected cells susceptible to lysis mediated via complement [3] . 
Why Do We Describe This Case

CASe PreSentAtIon
Miss AP was a 25-year-old female who was born in Malawi and had re-located to South Africa with her husband one year prior to consultation by the internal medicine service at Kalafong Tertiary Hospital. She was a primigravida and had a normal antenatal record except for the presence of a low hemoglobin. Other than her re-location to South Africa, our patient had no recent travel history to a malaria endemic area within South Africa.
At the time of consultation Miss AP had an estimated gestational age of 14 weeks with the initial consultation from the Obstetric service being for the establishment of the route cause of Miss AP's anemia.
Miss AP had been previously diagnosed with an anemia in Malawi for which she recalls numerous admissions for blood transfusions and specifically recalls receiving transfusions of PRBCs during bouts least two cell lines. The detection of GPIanchored proteins may be performed by labelling cells with monoclonal antibodies or a fluorescein-tagged proaerolysin (FLAER) reagent [4] . Bone marrow biopsy is not usually indicated in most cases.
Pregnancy is generally discouraged in patients with PNH due to the high risk of both fetal and maternal mortality. Anemia in a pregnant patient with PNH is sometimes more severe and more frequent transfusions of packed red blood cells (PRBCs) are required [5] . Owing to the occurrence of thrombosis in up to 40% of patients with PNH, the administration of low-molecularweight heparin (LMWH) is advised [1] . LMWH is generally administered from the time of confirmation of pregnancy to the end of the postpartum period [5] .
Eculizumab is a humanized monoclonal antibody directed against the complement Parvovirus B19 polymerase chain reaction performed on peripheral blood was negative.
Hemolysis specific investigations detected elevated levels of lactate dehydrogenase and low levels of haptoglobin (Table III) .
FLAER test and flow cytometry detected the presence of a PNH clone. Table IV shows the PNH panel. The expression of the GPI anchored proteins, CD55 (DAF) and CD59 (MIRL) was abnormal on both neutrophils and erythrocytes. Expression of the GPI-linked proteins (CD14 on monocytes and CD16 on neutrophils) was normal. In summary, there was phenotypic evidence of PNH based on analysis of a variety of GPI-linked antibodies on red blood cells and granulocytes.
A of malaria. Limited workup for the anemia had been performed in Malawi and a tentative diagnosis of a suspected aplastic anemia was made.
Vital signs recorded in Table I revealed a resting tachycardia with other vitals being within normal limits. Urine dipsticks revealed trace proteinuria and 1+ blood (weak positivity for blood).
General examination of our patient was unremarkable except for the presence of conjunctival rim pallor and non-pitting pedal edema.
Systems examination revealed a resting tachycardia with a left parasternal border systolic murmur. Abdominal examination revealed a palpable gravid uterus with the height of the uterine fundus at 14 cm. There was no palpable lymphadenopathy and no hepatosplenomegaly. Examination of the musculoskeletal system did not demonstrate any discrepancy in the diameter of the calves.
Blood tests revealed low levels of: white cell count, hemoglobin, and serum iron (Table II) .
Elevated levels of mean cell volume, red cell distribution width, total and direct/conjugated bilirubin, aspartate transaminase, fibrinogen, and D-dimers were also detected (Table II) .
The smear showed the presence of scanty red blood cell fragments.
Bone marrow aspirate demonstrated features of a megaloblastosis which may be in keeping with chronic hemolysis. Overall bone marrow aspirate revealed marked hypercellularity with normal lymphocyte morphology. The bone marrow aspirate did not reveal any features of plasmacytosis with no other foreign cells noted. two entities may show overlap in symptomatology (i.e. nausea, abdominal discomfort) and abnormal laboratory findings of intravascular hemolysis (elevated lactate dehydrogenase, elevated unconjugated bilirubin, low haptoglobin, and low platelet count) [2] .
PNH in pregnancy is associated with increased risks of complications such as thromboembolic diseases (e.g. Budd-Chiari syndrome), hypertensive disorders like preeclampsia, and cerebrovascular diseases. PNH in pregnancy can cause significant fetomaternal morbidity and mortality with the estimated maternal mortality ranging from 5.8% to 20.8%. More than 45% of pregnancies in women with PNH result in either spontaneous miscarriage or termination. Of the women who give birth, more than half deliver prematurely, an event that can have negative implications for the health of the new-born baby [3, 5] .
Eculizumab is a humanized monoclonal antibody that binds to the complement protein C5 and blocks terminal complement activation. During pregnancy eculizumab has shown a low rate of maternal complications up to now. However, expertise in managing pregnant patients with PNH with eculizumab is limited. In fact, prospective trials are unlikely to be initiated, due to the rarity of the disease. The drug is still listed in pregnancy as a category C drug («animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks» [7] ), but potential benefits may outweigh potential risks [5] . The cost of eculizumab, trade name Soliris ® , is approximately 18,000 USD per dose, making it one of the most expensive drugs in the United States [8] . The exorbitant cost of the drug makes its use in PNH in resource-constrained countries almost unjustified. 
Key Points
dISCuSSIon
PNH or Paroxysmal Nocturnal Hemoglobinuria is a rare disease entity which has a prevalence of 1-2 cases per million people [1] . The disease has a slight female preponderance and women of child-bearing potential are also affected [2] . The exact incidence of PNH in pregnancy is unknown and only case report data on PNH in pregnancy exists.
PNH is a non-neoplastic human disease caused by a somatic mutation of the X-linked phosphatidylinositol glycancomplementation class A gene in hematopoietic stem cells which makes red blood cells more vulnerable to lysis mediated by complement [1, 2] .
The long-term complications of PNH include a chronic intravascular hemolysis complicated by anemia, venous thromboembolism as well as bone marrow failure [1, 4] .
The clinical diagnosis of PNH in the setting of an obstetric patient can be a diagnostic challenge as the range of signs and symptoms present can be confounded with various pregnancy complications like preeclampsia, HELLP syndrome or pregnancy-associated thrombocytopenia. It is particularly important to try and distinguish a HELLP syndrome from a PNH crisis as the
